AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31699278
Drug: Men with
RxNorm normalized name: Peptamen with Prebio Vanilla
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Men with de novo heart failure undergoing reperfusion therapy
Trial: 31699827
Drug: AZD4573 (highly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD4573 (highly selective CDK9 inhibitor)
Trial: 31700871
Drug: JS001 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JS001 at 10 mg/kg
Trial: 31700871
Drug: JS001 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JS001 at 3 mg/kg
Trial: 31700871
Drug: JS001 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JS001 (all doses)
Trial: 31700924
Drug: Taodan granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taodan granules (TDKL), administered twice per day, 7 days per week, for 8 weeks.
Trial: 31700924
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered twice per day, 7 days per week, for 8 weeks.
Trial: 31700924
Drug: Taodan granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taodan granules (TDKL) and Placebo, both administered twice per day, 7 days per week, for 8 weeks.
Trial: 31701043
Drug: Negative pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative pressure wound therapy (NPWT) dressing (PICO™, Smith & Nephew, UK)
Trial: 31701169
Drug: Radiotherapy dose
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy dose reduced to cumulative 60 Gy with simultaneous chemotherapy regimen of cisplatin 30 mg/m²
Trial: 31701169
Drug: Standard multimodal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard multimodal treatments
Trial: 31703570
Drug: Reconsolidation Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reconsolidation Therapy (RT) - involves recalling traumatic events with propranolol, once a week for 10-25 minutes over 6 weeks
Trial: 31703637
Drug: Nivolumab 240
RxNorm normalized name: nivolumab 240 MG in 24 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 240 mg followed by palliative radiotherapy with 5 × 4 Gray (Gy) = 20 Gy photon radiation (Group A)
Trial: 31703728
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of eribulin (1.4 mg/m² daily) and everolimus (5 mg daily) at dose level A1
Trial: 31703728
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of eribulin and everolimus at dose level A2
Trial: 31703728
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of eribulin and everolimus at dose level B1
Trial: 31703728
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of eribulin and everolimus
Trial: 31703971
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment of RCC
Trial: 31704134
Drug: Denosumab 120
RxNorm normalized name: DENOSUMAB 120 MG/1.7 ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab 120 mg subcutaneously once every 4 weeks, with loading doses on days 8 and 15 for cohorts 1 and 2.
Trial: 31704214
Drug: Super-boosted lopinavir/ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Super-boosted lopinavir/ritonavir (LPV/r) 400/400 mg
Trial: 31705425
Drug: Myocardial substrate
RxNorm normalized name: BISMUTH SUBCITRATE
DrugBank: Bismuth subcitrate potassium (DB09275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Myocardial substrate metabolism in BTHS
Trial: 31706360
Drug: Swallowing and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swallowing and oral care (SOC) intervention
Trial: 31707795
Drug: Canagliflozin, dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin, dosage and duration not specified
Trial: 31707975
Drug: Ruxolitinib, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib, 20 mg orally twice daily for a 28-day cycle, continued for up to 16 cycles or until progressive disease or intolerability.
Trial: 31708167
Drug: Veliparib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib (250 mg BID) with chemotherapy (Regimen 1, continuous dosing)
Trial: 31708167
Drug: Veliparib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib (400 mg BID) with chemotherapy (Regimen 1, intermittent dosing)
Trial: 31708167
Drug: Veliparib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib (150 mg BID) with weekly paclitaxel (Regimen 2, continuous dosing)
Trial: 31708167
Drug: Veliparib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib (250 mg BID) with weekly paclitaxel (Regimen 2, intermittent dosing)
Trial: 31708167
Drug: Veliparib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib (150 mg BID) with intraperitoneal chemotherapy (Regimen 3, continuous dosing)
Trial: 31708167
Drug: Veliparib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib (400 mg BID) with intraperitoneal chemotherapy (Regimen 3, intermittent dosing)
Trial: 31708167
Drug: Veliparib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib (150 mg po BID) with chemotherapy (Regimens 1c, 2c, 2i, and 3c)
Trial: 31708167
Drug: Veliparib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib (250 mg po BID) with chemotherapy (Regimen 1i)
Trial: 31708167
Drug: Veliparib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib (300 mg po BID) with chemotherapy (Regimen 3i)
Trial: 31708167
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of continuous vs intermittent dosing of veliparib
Trial: 31708296
Drug: Neoadjuvant pembrolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant pembrolizumab (200 mg for three courses)
Trial: 31708810
Drug: ACCESS Integrated
RxNorm normalized name: sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ACCESS Integrated Care Model including Therapeutic Assertive Community Treatment
Trial: 31709259
Drug: Cholecalciferol supplementation
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol supplementation (800 IU daily for 6 months)
Trial: 31710189
Drug: Vaginal sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal sildenafil (suppository-100 mg/daily)
Trial: 31710189
Drug: Vaginal placebo/sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal placebo/sildenafil (suppository-100 mg/daily)
Trial: 31710189
Drug: Vaginal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal placebo (suppository)
Trial: 31710684
Drug: Therapies and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapies and side effects experienced by patients
Trial: 31712075
Drug: Management of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Management of pain with opioid analgesics
Trial: 31712344
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy delay
Trial: 31712349
Drug: Antineoplastic drugs
RxNorm normalized name: Platinum compounds, antineoplastic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antineoplastic drugs (AD) exposure in nursing staff
Trial: 31712813
Drug: Gentamicin 360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin 360 mg intramuscular dose
Trial: 31713056
Drug: Structured daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured daily hip exercise regimen (extension and external rotation)
Trial: 31714428
Drug: Duration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of antiretroviral therapy use (particularly related to protease inhibitor use)
Trial: 31719077
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose of opioids with NSAIDs
Trial: 31719077
Drug: 50% overall
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% overall reduction in opioid dosage, dose-extending placebos and NSAIDs
Trial: 31720254
Drug: Flaxseed enriched
RxNorm normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed enriched yogurt (200 g 2.5% fat yogurt containing 30-g flaxseed)
Trial: 31720293
Drug: Fluticasone furoate/umeclidinium/vilanterol
RxNorm normalized name: Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; Trelegy) delivered by the ELLIPTA inhaler, once daily for 24 weeks
Trial: 31721017
Drug: Spebrutinib 375
RxNorm normalized name: Spebrutinib
DrugBank: Spebrutinib (DB11764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spebrutinib 375 mg/day
Trial: 31721246
Drug: Sirolimus (SRL)
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus (SRL) monotherapy withdrawal over ~6 months
Trial: 31721246
Drug: Sirolimus (SRL)
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus (SRL) monotherapy withdrawal
Trial: 31721643
Drug: Atezolizumab 1,200
RxNorm normalized name: atezolizumab 1,200 mg/20 mL (60 mg/mL) INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab 1,200 mg and Bevacizumab 15 mg/kg intravenously every 3 weeks
Trial: 31722951
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy applied to craniomandibular structures, with four weekly sessions.
Trial: 31723056
Drug: Labyrinth Devices
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labyrinth Devices Multichannel Vestibular Implant System vestibular implant
Trial: 31723767
Drug: Idelalisib in
RxNorm normalized name: Product containing idelalisib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idelalisib in combination with Rituximab (IR)
Trial: 31723767
Drug: Idelalisib in
RxNorm normalized name: Product containing idelalisib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idelalisib in combination with Bendamustine (IB)
Trial: 31723767
Drug: Idelalisib in
RxNorm normalized name: Product containing idelalisib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idelalisib in combination with both Rituximab and Bendamustine (IBR)
Trial: 31724813
Drug: Talazoparib (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talazoparib (600 µg/m) in combination with low-dose temozolomide (TMZ)
Trial: 31725015
Drug: BET inhibitor
RxNorm normalized name: BET INHIBITOR TEN-010
DrugBank: RO-6870810 (DB15151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BET inhibitor apabetalone
Trial: 31725459
Drug: Antiviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral therapy for 78 weeks
Trial: 31726422
Drug: Proprotein convertase
RxNorm normalized name: Proprotein convertase 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i)
Trial: 31727136
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of suPAR and CRP
Trial: 31729626
Drug: Peficitinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peficitinib (150 mg single oral dose)
Trial: 31730164
Drug: IV administration
RxNorm normalized name: IV Administration Set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV administration of ertapenem (1 g once daily)
Trial: 31730497
Drug: Conventional synthetic
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) including methotrexate (MTX)
Trial: 31732655
Drug: Increased prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased prescription of P2Y
Trial: 31733180
Drug: Rivaroxaban at
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban at a dose of 10 mg daily (with aspirin at a dose of 75 to 100 mg daily for the first 3 months)
Trial: 31733180
Drug: Antiplatelet group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet group (aspirin at a dose of 75 to 100 mg daily with clopidogrel at a dose of 75 mg daily for the first 3 months)
Trial: 31734820
Drug: Dotinurad 1
RxNorm normalized name: Dotinurad
DrugBank: Dotinurad (DB16145)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Dotinurad 1 mg for 7 days
Trial: 31734820
Drug: Topiroxostat 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiroxostat 80 mg (concomitant use with Dotinurad)
Trial: 31734832
Drug: RO6839921 (14-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO6839921 (14-120 mg AP)
Trial: 31735436
Drug: VKAs (warfarin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VKAs (warfarin, acenocoumarol)
Trial: 31738180
Drug: Artificial intelligence-driven
RxNorm normalized name: Intelence
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artificial intelligence-driven monitoring solution with automatic alerts
Trial: 31738180
Drug: Artificial intelligence-driven
RxNorm normalized name: Intelence
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artificial intelligence-driven monitoring solution
Trial: 31738181
Drug: Early AKI
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early AKI (defined by an increase in serum creatinine >0.3 mg/dl or urine output <1 ml/kg per hour on postnatal days 2-7)
Trial: 31738425
Drug: larotrectinib (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: larotrectinib (20 mg/kg twice daily)
Trial: 31740479
Drug: Gender-affirming hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gender-affirming hormone therapy in transgender men (TM)
Trial: 31740479
Drug: Gender-affirming hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gender-affirming hormone therapy in transgender women (TW)
Trial: 31741786
Drug: Muscular Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muscular Group (MG)
Trial: 31742564
Drug: Lower vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower vitamin D group (<25 ng/ml), n=22
Trial: 31742564
Drug: Higher vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher vitamin D group (≥25 ng/ml), n=21
Trial: 31744781
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitors (SSRI) mono-class therapy
Trial: 31744781
Drug: Antipsychotic-containing regimens
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic-containing regimens
Trial: 31744895
Drug: ERK Inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERK Inhibitor LY3214996
Trial: 31749854
Drug: Diffusing alpha
RxNorm normalized name: alpha tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diffusing alpha emitters radiation therapy (DaRT) applied to one lesion.
Trial: 31750307
Drug: Three different
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three different exercise strategies, details on dosage and duration not available
Trial: 31750837
Drug: Standard self-monitoring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard self-monitoring app (cognitive behavioral therapy-based)
Trial: 31752504
Drug: Extended follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended follow-up intervals for INR monitoring, specific dosage and duration not available
Trial: 31752504
Drug: Standard follow-up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard follow-up intervals for INR monitoring, specific dosage and duration not available
Trial: 31752752
Drug: Oral metformin
RxNorm normalized name: metformin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metformin at doses up to 3000 mg per day for 3 months
Trial: 31752951
Drug: Dual-mobility cup
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-mobility cup and cementless triple-taper femoral stem combination
Trial: 31752976
Drug: Delay to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delay to appropriate antimicrobial treatment
Trial: 31752976
Drug: Prolonged antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged antimicrobial therapy (>7 days)
Trial: 31753019
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with anti-BTLA antibody
Trial: 31753029
Drug: Atezolizumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (15 mg/kg every 3 weeks for patients < 18 years; 1200 mg every 3 weeks for patients ≥ 18 years)
Trial: 31756197
Drug: Delayed antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed antibiotic prescription
Trial: 31758682
Drug: DAAO method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAAO method with phenylalanine intake of 15 mg · kg-1 · d-1 during early pregnancy
Trial: 31758682
Drug: DAAO method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAAO method with phenylalanine intake of 21 mg · kg-1 · d-1 during late pregnancy
Trial: 31758682
Drug: IAAO method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IAAO method with phenylalanine intake of 21 mg · kg-1 · d-1 during late pregnancy
Trial: 31760835
Drug: 7 +
RxNorm normalized name: menaquinone 7
DrugBank: Menaquinone 7 (DB13075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 + 3/5 + 2 chemotherapy
Trial: 31760881
Drug: Treatment Satisfaction
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Satisfaction Questionnaire, 9 items (TSQM-9)
Trial: 31760881
Drug: Morisky Medication-Taking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morisky Medication-Taking Adherence Scale (MMAS-4)
Trial: 31763491
Drug: 36-ingredient micronutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 36-ingredient micronutrient supplement
Trial: 31764746
Drug: Low-molecular-weight (LMW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight (LMW) heparin plus aspirin (n=93)
Trial: 31764746
Drug: Aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin alone (n=94)
Trial: 31767018
Drug: Adenosine stress
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine stress (140 microg/kg/min infusion)
Trial: 31767018
Drug: Rest (following
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rest (following intravenous contrast bolus 0.05 mmol/kg, gadobutrol)
Trial: 31767463
Drug: VAX-ID® intradermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAX-ID® intradermal injection technique
Trial: 31767533
Drug: Very-accelerated partial
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very-accelerated partial breast irradiation (vAPBI) using single fraction of multicatheter interstitial high-dose rate brachytherapy (MIB) at a dose of 16 Gy.
Trial: 31767578
Drug: Polymorphisms of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymorphisms of genes related to vitamin D metabolism and transportation
Trial: 31767591
Drug: Multicomponent preoperative
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multicomponent preoperative and intraoperative intervention including systematic information, preoperative screening, nutrient supplementation, physical exercise, medication review, blood management, carbohydrate loading, orientation aids, and geriatric anaesthesia concept
Trial: 31768261
Drug: Individualized follow-up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized follow-up through a smartphone application (app) on a weekly basis for one year.
Trial: 31768262
Drug: 150,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150,000 IU loading dose vitamin D
Trial: 31769793
Drug: GSK2838232 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2838232 (20 mg) with cobicistat 150 mg
Trial: 31769793
Drug: GSK2838232 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2838232 (50 mg) with cobicistat 150 mg
Trial: 31769793
Drug: GSK2838232 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2838232 (100 mg) with cobicistat 150 mg
Trial: 31769793
Drug: GSK2838232 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2838232 (200 mg) with cobicistat 150 mg